NEW YORK (GenomeWeb) – Single-cell proteomics firm IsoPlexis said today that it has received a $4 million Small Business Innovation Research (SBIR) grant from the National Cancer Institute.
The Branford, Connecticut-based company said that it will use the funds to commercialize its IsoLight platform for use in quality control and guidance of CAR T therapy.